Despite the growth in gastroenterology, "Psoriasis" remains the largest revenue-generating indication for the ustekinumab market in 2026. In 2026, the market for moderate-to-severe plaque psoriasis is identifying as a "saturated but stable" segment, with millions of long-term users maintaining their skin clearance through ustekinumab. This 2026 trend is driven by the drug’s proven safety profile over nearly two decades of use, which makes it a "comfort brand" for dermatologists even in the face of newer, slightly more potent competition. However, 2026 is also seeing a rise in "pediatric" applications, as the drug's approval for children as young as 6 years old opens up a new, high-growth demographic for long-term treatment.

The resilience of the dermatology segment is a primary driver within the Ustekinumab Market. As of January 2026, "Adult" patients still make up the majority of the market, but the "Geriatric" segment is identified as a fast-growing niche due to the rising incidence of psoriatic arthritis in aging populations. This 2026 movement is also fostering a market for "Value-Added Services," where manufacturers provide patients with digital skin-tracking apps to monitor their progress and share photos directly with their doctors. The 2026 market proves that even a mature drug can find new life by focusing on specific, underserved age groups.

Do you think that a drug with 20 years of safety data is better than a brand-new drug that might be slightly more effective? Please leave a comment!

#Dermatology2026 #SkinHealth #PsoriasisAwareness #PediatricCare #PharmaHistory